Most Clicked AABB SmartBrief Stories

1. AABB posts transcript from "Ask the FDA and CMS/CLIA" session

AABB SmartBrief | Jan 23, 2015

A transcript from the "Ask the FDA and CMS/CLIA" session that took place during the 2014 AABB Annual Meeting is now available online. Experts responded to questions about technical consultant qualifications under CLIA moderate/high complexity testing requirements, competency assessments and proficiency testing requirements. In addition, panelists addressed questions related to platelet dating and bacterial testing of platelets; clarification of syphilis results notification recommendations from the 2014 guidance; processing changes made by cord blood manufacturers that may require a supplement; current considerations for Hematopoietic Progenitor Cell Apheresis products; medical device data systems; laboratory-developed tests; and FDA plans for interventions to prevent transfusion transmission of the chikungunya, dengue and Ebola viruses. Blank (01/23)

2. Stem cell therapy benefits patients with early multiple sclerosis, study finds

AABB SmartBrief | Jan 21, 2015

Preliminary data from a small study in the Journal of the American Medical Association has found that patients in the earlier stages of multiple sclerosis benefit from treatment with autologous nonmyeloablative hematopoietic stem cells. Half of the participants who were followed for two years had significant improvements on a standard measure of disability. HealthDay News (01/20) San Diego Union-Tribune (01/20)

3. Stem cells derived from amniotic membrane have immunosuppressive properties

AABB SmartBrief | Jan 20, 2015

A study in the journal Cell Transplantation has found that stem cells from amniotic tissues have immunosuppressive properties. Amnion-derived cells had an inhibitory effect on natural killer cells and induced the activation of white blood cells, and the effect may be driven by high levels of interleukin-10 and the presence of prostaglandin E2. Genetic Engineering & Biotechnology News (01/19)

4. Organs transplanted from newborn donor in U.K.

AABB SmartBrief | Jan 20, 2015

The kidneys as well as liver cells from a 6-day-old newborn were donated to two patients in the U.K., according to a case report in the journal Archives of Disease in Childhood. The Royal College of Paediatrics and Child Health is reviewing U.K. guidelines that restrict declarations of brain death in infants younger than 2 months. BBC (01/19)

5. Blood test diagnoses heart attacks in women

AABB SmartBrief | Jan 22, 2015

A new blood test is twice as effective at diagnosing heart attacks in women than a test currently used in the U.K., according to a 1,126-patient study in The BMJ. The test detects very small levels of the heart attack biomarker troponin. A 26,000-patient study is being planned. BBC (01/21) PharmaTimes (U.K.) (01/21)

6. Fecal transplant treats Crohn's disease, ulcerative colitis in animal studies

AABB SmartBrief | Jan 23, 2015

University of Utah researchers have found that fecal transplants appear to reverse autoimmune diseases of the bowel such as Crohn's disease and ulcerative colitis in mice. The transplant of fecal material in mice via a tube into the stomach restored the balance of intestinal flora and normalized the intestines' function. The study appears in the journal Cell Host & Microbe. Voice of America (01/22)

7. Study examines oral anticoagulant therapy for antiphospholipid syndrome

AABB SmartBrief | Jan 22, 2015

The use of new oral direct thrombin and factor Xa inhibitors such as dabigatran and rivaroxaban was associated with an 86.6% event-free survival rate after 12 months for patients with antiphospholipid syndrome, according to a study presented at a meeting of the American College of Rheumatology. The 24-patient, multi-center study supports the use of oral direct inhibitors as an alternative therapy, according to researchers. Healio (free registration) (01/21)

8. Normal D-dimer levels after anticoagulation linked with reduced risk of thromboembolism

AABB SmartBrief | Jan 23, 2015

Women who achieved normal D-dimer levels after anticoagulant treatment for a first venous thromboembolism were at lower risk for recurrence, according to a study in the Annals of Internal Medicine. The study of 410 patients found support for stopping anticoagulation therapy in women but not men based on D-dimer levels. Healio (free registration) (01/21)

9. Cell transplant effective against mevalonate kinase deficiency, case report finds

AABB SmartBrief | Jan 19, 2015

A child in Italy who received an allogeneic hematopoietic stem cell transplant to treat mevalonate kinase deficiency is doing well five years after treatment, according to a case report in the journal Pediatrics. Transplants should be considered for patients who do not respond to anticytokine drugs, according to the authors. Healio (free registration) (01/16)

10. Few hemorrhagic stroke patients receive prophylactic anticoagulation, analysis finds

AABB SmartBrief | Jan 19, 2015

A minority of patients with intracerebral hemorrhage receive prophylactic anticoagulation for deep vein thrombosis, according to a study in the journal Stroke. Researchers analyzed data on 32,690 adults treated for ICH from 2006 to 2010 and found 16.5% received prophylactic anticoagulation. The rate rose from 15.0% before the 2007 release of guidelines that recommend low-dose unfractionated heparin or low-molecular weight heparin to 17.5% afterward. Medscape (free registration) (01/16)

Sign up for AABB SmartBrief

Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more